目的 观察康复新液防治头颈部恶性肿瘤患者急性放射性口腔炎的效果。方法 68例患者随机分为康复新液组和对照组,各34例。自放射治疗开始至放疗结束,康复新液组予康复新液含服,每次10-15 m L,每天3-5次,对照组予维生素B1210 mg＋维生素B2...目的 观察康复新液防治头颈部恶性肿瘤患者急性放射性口腔炎的效果。方法 68例患者随机分为康复新液组和对照组,各34例。自放射治疗开始至放疗结束,康复新液组予康复新液含服,每次10-15 m L,每天3-5次,对照组予维生素B1210 mg＋维生素B250 mg＋2%利多卡因5 m L＋地塞米松5 mg＋0.9%氯化钠注射液250 m L混合液口腔含漱,每次10-15 m L,每天3-5次。每周观察两组患者口腔黏膜反应并进行疼痛评分。结果 放疗第3周开始,康复新液组发生放射性口腔炎的程度均低于对照组（P〈0.05或P〈0.01）。放疗第3、5、6、7周康复新液组的疼痛评分（2.94±2.23）、（4.44±2.62）、（4.32±2.40）、（4.12±2.25）分,均分别低于对照组的（4.59±2.27）、（5.79±2.32）、（6.00±2.37）、（6.12±2.45）分（P〈0.05或P〈0.01）。结论 康复新液有助于降低头颈部恶性肿瘤患者放疗后放射性口腔炎的严重程度和口腔黏膜疼痛程度,有效提高生活质量。展开更多
目的分析探讨头颈部恶性肿瘤(head and neck cancer,HNC)患者放射治疗(放疗)结束时的营养不良状况与营养相关症状和生活质量的关系。方法通过便利抽样法选择2018年12月至2020年1月于北京某肿瘤医院放疗科门诊头颈组完成放疗的HNC患者为...目的分析探讨头颈部恶性肿瘤(head and neck cancer,HNC)患者放射治疗(放疗)结束时的营养不良状况与营养相关症状和生活质量的关系。方法通过便利抽样法选择2018年12月至2020年1月于北京某肿瘤医院放疗科门诊头颈组完成放疗的HNC患者为横断面研究对象。采用以下3种标准进行营养不良评定:体重指数(body mass index,BMI)<18.5 kg/m^2伴一般情况差(简称BMI标准);营养风险筛查2002评分(nutritional risking screening 2002,NRS 2002)营养状态受损评分为3分(简称NRS 2002标准);全球(营养)领导人诊断营养不良标准(global leadership initiative on malnutrition,GLIM)但不包括肌肉量测定(简称GLIM标准),并根据GLIM标准将患者分为营养不良与营养正常两组。采用头颈部患者症状调查表调查营养相关症状情况。采用欧洲癌症研究与治疗组织生活质量核心评定量表调查生活质量。结果共210例HNC患者纳入分析,根据BMI标准,19例(9.0%)患者存在营养不良;根据NRS 2002标准,110例(52.4%)患者存在营养不良;根据GLIM标准,145例(69.0%)患者存在营养不良。发生率>80.0%的营养相关症状有疼痛、口干、唾液黏稠和味觉改变,对进食干扰程度>3分的营养相关症状有疼痛、吞咽困难、口腔溃疡、味觉改变和食欲不振;总体健康状况得分为(51.47±21.48)分。营养不良患者与营养正常患者相比,营养相关症状频率总分更高(40.09±9.23)分比(33.63±9.13)分,P<0.01;对进食干扰程度总分更高(30.97±6.53)分比(25.85±6.54)分,P<0.01;而总体健康状况得分则更低(48.10±20.59)分比(58.97±21.67)分,P=0.001。结论HNC患者放疗结束时营养不良发生率高,营养相关症状普遍且对进食影响大,营养不良患者的营养相关症状更多、更重,生活质量更差,提示医护人员应持续关注放疗结束后HNC患者的营养状况和营养相关症状情况,进行营养干预及症状管理,以改善其生活质量。展开更多
It has been expected that chemotherapy,as one of the major modalities in the management of cancer,would exert some beneficial effects on head and neck tumors.However,most of the pathologic types of head and neck solid...It has been expected that chemotherapy,as one of the major modalities in the management of cancer,would exert some beneficial effects on head and neck tumors.However,most of the pathologic types of head and neck solid carcinoma are of squamous cell variety,which seems no long-term radical response to any regimens of chemotherapy so far,according to the literature reports since the advent of chemotherapy.It is suggested at present no chemotherapy be applied to head and neck cancer patients for the purpose of a radical cure,which could be brought about by surgery or radiotherapy.Some of the literature that advocated chemotherapy on head and neck cancer is unjustifiable,not without personal bias.Clinical investigation should be further conducted on a small scale and in a rigorous way at research units in order to find a curative and treatment advice for head and neck oncologists in future.展开更多
文摘目的 观察康复新液防治头颈部恶性肿瘤患者急性放射性口腔炎的效果。方法 68例患者随机分为康复新液组和对照组,各34例。自放射治疗开始至放疗结束,康复新液组予康复新液含服,每次10-15 m L,每天3-5次,对照组予维生素B1210 mg＋维生素B250 mg＋2%利多卡因5 m L＋地塞米松5 mg＋0.9%氯化钠注射液250 m L混合液口腔含漱,每次10-15 m L,每天3-5次。每周观察两组患者口腔黏膜反应并进行疼痛评分。结果 放疗第3周开始,康复新液组发生放射性口腔炎的程度均低于对照组（P〈0.05或P〈0.01）。放疗第3、5、6、7周康复新液组的疼痛评分（2.94±2.23）、（4.44±2.62）、（4.32±2.40）、（4.12±2.25）分,均分别低于对照组的（4.59±2.27）、（5.79±2.32）、（6.00±2.37）、（6.12±2.45）分（P〈0.05或P〈0.01）。结论 康复新液有助于降低头颈部恶性肿瘤患者放疗后放射性口腔炎的严重程度和口腔黏膜疼痛程度,有效提高生活质量。
文摘It has been expected that chemotherapy,as one of the major modalities in the management of cancer,would exert some beneficial effects on head and neck tumors.However,most of the pathologic types of head and neck solid carcinoma are of squamous cell variety,which seems no long-term radical response to any regimens of chemotherapy so far,according to the literature reports since the advent of chemotherapy.It is suggested at present no chemotherapy be applied to head and neck cancer patients for the purpose of a radical cure,which could be brought about by surgery or radiotherapy.Some of the literature that advocated chemotherapy on head and neck cancer is unjustifiable,not without personal bias.Clinical investigation should be further conducted on a small scale and in a rigorous way at research units in order to find a curative and treatment advice for head and neck oncologists in future.
